Arrowhead to Present at Upcoming Conferences

PASADENA, Calif. — November 7, 2013 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on the Dynamic Polyconjugate (DPC) siRNA delivery technology at two upcoming scientific conferences.

Scheduled conference presentations include the following:

EuroTIDES 2013 – Prague, Czech Republic, November 13-14

November 14, 2013 – An oral presentation titled, “DPC technology for delivery of therapeutic siRNAs,” will be presented by David Lewis, Ph.D., Chief Scientific Officer;

Oligonucleotide & Peptide Based Therapeutics Congress – San Diego, CA, USA, November 18-19

November 19, 2013 – An oral presentation titled, “Targeted delivery of therapeutic siRNAs using DPC technology,” will be presented by David Lewis, Ph.D., Chief Scientific Officer.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com